Imagine waking up on your child’s birthday, not with joy, but with a panic attack. That’s the reality for Tammy McDaid, a Swansea mum whose five-year-old son, Tate, is battling a rare and devastating condition: Sanfilippo Syndrome, often called 'childhood dementia.' But here’s where it gets controversial—while there’s no cure, a new drug on the horizon could change everything. And this is the part most people miss: the next 365 days could be make-or-break for Tate’s future.
Sanfilippo Syndrome is a neurodegenerative disorder that affects just over 100 children in the UK. It’s like Alzheimer’s, but in kids. The condition steals abilities like walking, talking, and even eating, often progressing rapidly after age five. For Tammy, the thought of Tate losing his mobility is one of the hardest things to face. 'He’s my handsome little man,' she says, 'and I’ll do anything to give him a better quality of life.'
The family’s hope rests on a drug called UX111, which could be approved in the US later this year. If it gets the green light, Tate might start treatment by summer, potentially slowing the disease’s progression. But here’s the catch: accessing this treatment isn’t cheap. Tammy has already raised £35,000 for a clinical trial, but the costs could soar into the hundreds of thousands, especially with a year of monitoring in the US. 'We’ll get there,' she says determinedly, but the financial and emotional toll is immense.
And this is where it gets even more complex—should families like Tammy’s have to fight so hard for potentially life-changing treatments? Is it fair that access to such drugs often depends on fundraising and geographic location? These are questions that spark debate, and Tammy’s story invites us to think deeply about the inequities in healthcare.
Meanwhile, Tammy is focusing on 'living in the moment' with Tate. They recently celebrated their birthdays (just two days apart) in Fuerteventura, where Tate, a 'water baby,' splashed in pools and explored a water park. 'It was nice to forget reality for a while,' Tammy shares. She’s also planning trips to Germany and collecting fridge magnets from every country they visit—a simple yet beautiful way to make memories.
Tate’s progress is heartwarming. He started full-time school in September, interacts with peers, and even helps around the house. 'One day, he took off his shoes and put his socks in the washing machine before I could even settle in,' Tammy recalls, her pride palpable. She’s also hopeful about intensive speech therapy, as Tate is non-verbal, and wants to raise awareness about childhood dementia through her advocacy.
But here’s the thought-provoking question: What if this drug works for Tate—what does it mean for the hundreds of other children with Sanfilippo Syndrome? And what if it doesn’t? Tammy’s journey isn’t just about her son; it’s a call to action for more research, funding, and compassion. Her story challenges us to consider: How far would you go for your child? And what can we do collectively to ensure no family faces this battle alone?
As Tammy says, 'I know it’s not a cure, but it could give him a significantly better life.' Let’s hope her fight—and Tate’s resilience—inspires change. What’s your take? Share your thoughts in the comments.
